By Gareth John MacDonald – Genetic Engineering & Biotechnology News –
A new generation of automated technologies in cell and gene therapy manufacturing systems will help more people benefit according to research identifying high production cost as the main impediment to access.
The authors of a new study reached this conclusion after looking at factors determining the success—or failure—of cell and gene therapies developed for children.
Lead author Crystal Mackall, MD, founding director of the Stanford Center for Cancer Cell Therapy, told GEN: “Autologous cell therapies are more expensive to produce than small molecules or biologics because each product is individualized and requires a dedicated workflow.
